What's Happening?
At the LSX World Congress, Paulo Neves, CMO of Xeltis, discussed the company's progress in developing implants that enable natural tissue restoration for vascular diseases. Xeltis aims to improve care standards for patients undergoing vascular surgery,
addressing unmet needs in haemodialysis access and coronary arterial bypass surgery. The company is focused on creating living, long-lasting vessels, which could revolutionize treatment for millions of patients worldwide.
Why It's Important?
Xeltis' technology could significantly enhance outcomes for patients with vascular diseases, reducing the need for repeat surgeries and improving quality of life. The approach of endogenous tissue restoration represents a shift towards more sustainable and effective treatments. Successful implementation could lead to widespread adoption in the medical community, influencing future research and development in vascular therapies.
